MdBio Leadership Series
Breakfast with Peter Greenleaf, President of MedImmune
The State of the Life Sciences Industry
The biopharmaceutical industry has experienced major changes in the past few years with more changes expected to come. MdBio is proud to have Mr. Greenleaf provide his perspectives of the state of the global biotech industry and critical business/regulatory/government issues impacting the industry.
As Chairman of the Maryland Venture Fund Authority, Mr. Greenleaf will also discuss recent developments within the Maryland life sciences industry, including an implementation update of the InvestMaryland Program.
MedImmune’s experience is a model for the Maryland life sciences community. Mr. Greenleaf will discuss MedImmune’s evolution as AstraZeneca’s global biologics arm and discuss opportunities for Maryland life sciences companies to showcase themselves on the global stage.